Inactivated COVID-19 vaccine triggering hemophagocytic lymphohistiocytosis in an immunocompetent adult - A case report
Background and Aim: Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome that is induced by hyper-activated macrophages, cytotoxic T cells, and reduced natural killer cell activity. A 46-year-old gentleman presented to us with complaints of intermittent fever for the past 2 weeks associated with fatigue along with oral ulcers and skin rashes which resolved spontaneously. These symptoms started after he received the second dose of the BBIP-CorV COVID-19 vaccine. His complete blood picture showed pancytopenia. A detailed infectious disease workup was unrevealing; however, his bone marrow biopsy revealed increased histiocyte activity, with some showing hemophagocytosis and dysplasia. Immunohistochemistry profile demonstrated strong CD 68 positivity. Further investigations showed raised serum ferritin and fasting triglyceride levels. He was immediately started on dexamethasone acetate at a dose of 10 mg/m2 , after which his clinical symptoms, as well as his blood parameters, improved remarkably. This is the first documented case in Pakistan.
Conclusion: The data from clinical trials support the general safety profile of inactivated COVID-19 vaccines. We endorse its mass implementation. However, we believe that robust data need to be generated to evidence any adverse events, especially those with serious outcomes. Physicians should be aware of inactivated COVID-19 vaccine as a possible trigger for HLH and start prompt treatment, resulting in favorable outcomes.
Relevance for Patients: The presentation of HLH may vary and can present in an immunocompetent patient with no underlying risk factor. HLH should be kept in differentials when a patient presents with pancytopenia with a recent history of receiving COVID-19 vaccination. Steroids play a major role in the treatment of HLH, and definitive diagnosis and early treatment improve clinical outcomes.
[1] La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the Management of Hemophagocytic Lymphohistiocytosis in Adults. Blood J Am Soc Hematol 2019;133:2465-77.
[2] Majumder A, Sen D. An Autopsy Series of an Oftmissed Ante-mortem Diagnosis: Hemophagocytic Lymphohistiocytosis. Autops Case Rep 2021;11:e2021243.
[3] Grzybowski B, Vishwanath VA. Hemophagocytic Lymphohistiocytosis: A Diagnostic Conundrum. J Pediatr
Neurosci 2017;12:55.
[4] Liederman Z. Hemophagocytic Lymphohistiocytosis Associated with Adult Vaccination: A Case of Cytokine
Flurries. Can J Gen Intern Med 2015;10:32.
[5] Madkaikar M, Shabrish S, Desai M. Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis (HLH). Indian J Pediatr 2016;83:434-43.
[6] Campo M, Berliner N. Hemophagocytic Lymphohistiocytosis in Adults. Hematology Oncol Clin North Am 2015;29:915-25.
[7] Allen CE, McClain KL. Pathophysiology and Epidemiology of Hemophagocytic Lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2015;2015:177-82.
[8] Bode SF, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ, et al. Recent Advances in the Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis. Arthritis Res Ther 2012;14:213.
[9] Henter J. Diagnostic Guidelines for Hemophagocytic Lymphohistiocytosis. The FHL Study Group of the
Histiocyte Society. Semin Oncol 1991;18:29-33.
[10] Tholin B, Hauge MT, Aukrust P, Fehrle L, Tvedt TH. Hemophagocytic Lymphohistiocytosis in a Patient with
COVID-19 Treated with Tocilizumab: A Case Report. J Med Case Rep 2020;14:187.
[11] Ikebe T, Takata H, Sasaki H, Miyazaki Y, Ohtsuka E, Saburi Y, et al. Hemophagocytic Lymphohistiocytosis
Following Influenza Vaccination in a Patient with Aplastic Anemia Undergoing Allogeneic Bone Marrow Stem Cell Transplantation. Int J Hematol 2017;105:389-91.
[12] Wiseman D, Lin J, Routy JP, Samoukovic G. Haemophagocytic Lymphohistiocytosis in an Adult with Postacute COVID-19 Syndrome. BMJ Case Rep 2021;14:e245031.
[13] Dandu H, Yadav G, Malhotra HS, Pandey S, Sachu R, Dubey K. Hemophagocytic Histiocytosis in Severe SARSCoV-2 Infection: A Bone Marrow Study. Int J Lab Hematol 2021;43:1291-301.
[14] Soy M, Atagündüz P, Atagündüz I, Sucak GT. Hemophagocytic Lymphohistiocytosis: A Review Inspired
by the COVID-19 Pandemic. Rheumatol Int 2021;41:7-18.
[15] Tang LV, Hu Y. Hemophagocytic Lymphohistiocytosis after COVID-19 Vaccination. J Hematol Oncol 2021;14:1-5.
[16] Attwell L, Zaw T, McCormick J, Marks J, McCarthy H. Haemophagocytic Lymphohistiocytosis after ChAdOx1 nCoV-19 Vaccination. J Clin Pathol 2022;75:282-4.
[17] Cory P, Lawrence H, Abdulrahim H, MahmoodRao H, Hussein A, Gane J. Lessons of the Month 3: Haemophagocytic Lymphohistiocytosis Following COVID-19 Vaccination (ChAdOx1 nCoV-19). Clin Med
(London, England) 2021;21:e677-9.
[18] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and Immunogenicity of an Inactivated SARSCoV-2 Vaccine, BBIBP-CorV: A Randomised, Doubleblind, Placebo-controlled, Phase 1/2 Trial. Lancet Infect Dis 2021;21:39-51.
[19] Manuel RC, Pilar BZ, Armando LG. Munther AK, Xavier B. Adult Haemophagocytic Syndrome. Lancet
2014;383:1503-16.